Attributes | Values |
---|
rdf:type
| |
Description
| - Despite optimal primary treatment, with adequate surgery with or without adjuvant chemotherapy, 30%–50% of patients with colon cancer will relapse and die of their disease. The principal aim of follow-up programmes after curative resection of colorectal cancer is to improve survival (Gan et al., 2007). To achieve this goal, patients are screened for early recurrent disease with the intent of a second curative surgery. Patients with a history of colorectal cancer are also at risk to develop new primary colorectal cancers (CRC). The risk of development of new primary lesions has been estimated to 0,35% per year (Cali et al.,1993). Bouvier et al reported the incidence of metachronous cancer as being 1.8% at five years, 3.4% at 10 years, and 7.2% at 20 years with the greatest excess risk between one and five years post-surgery(Bouvier et al. 2008).
- Despite optimal primary treatment, with adequate surgery with or without adjuvant chemotherapy, 30%–50% of patients with colon cancer will relapse and die of their disease. The principal aim of follow-up programmes after curative resection of colorectal cancer is to improve survival (Gan et al., 2007). To achieve this goal, patients are screened for early recurrent disease with the intent of a second curative surgery. Patients with a history of colorectal cancer are also at risk to develop new primary colorectal cancers (CRC). The risk of development of new primary lesions has been estimated to 0,35% per year (Cali et al.,1993). Bouvier et al reported the incidence of metachronous cancer as being 1.8% at five years, 3.4% at 10 years, and 7.2% at 20 years with the greatest excess risk between one and five years post-surgery(Bouvier et al. 2008). (en)
|
Title
| - Follow up and recurrence of colorectal cancer
- Follow up and recurrence of colorectal cancer (en)
|
skos:prefLabel
| - Follow up and recurrence of colorectal cancer
- Follow up and recurrence of colorectal cancer (en)
|
skos:notation
| - RIV/00064190:_____/12:#0000391!RIV13-MZ0-00064190
|
http://linked.open...avai/predkladatel
| |
http://linked.open...avai/riv/aktivita
| |
http://linked.open...avai/riv/aktivity
| |
http://linked.open...vai/riv/dodaniDat
| |
http://linked.open...aciTvurceVysledku
| |
http://linked.open.../riv/druhVysledku
| |
http://linked.open...iv/duvernostUdaju
| |
http://linked.open...titaPredkladatele
| |
http://linked.open...dnocenehoVysledku
| |
http://linked.open...ai/riv/idVysledku
| - RIV/00064190:_____/12:#0000391
|
http://linked.open...riv/jazykVysledku
| |
http://linked.open.../riv/klicovaSlova
| - chemotherapy; Colorectal Cancer (en)
|
http://linked.open.../riv/klicoveSlovo
| |
http://linked.open...ontrolniKodProRIV
| |
http://linked.open...i/riv/nazevZdroje
| - Colorectal Cancer - From Prevention to Patient Care
|
http://linked.open...in/vavai/riv/obor
| |
http://linked.open...ichTvurcuVysledku
| |
http://linked.open...v/pocetStranKnihy
| |
http://linked.open...cetTvurcuVysledku
| |
http://linked.open...UplatneniVysledku
| |
http://linked.open...iv/tvurceVysledku
| |
number of pages
| |
http://bibframe.org/vocab/doi
| |
http://purl.org/ne...btex#hasPublisher
| |
https://schema.org/isbn
| |
is http://linked.open...avai/riv/vysledek
of | |